Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Revenue for the quarter came in at $418.2 million versus the consensus estimate of $413.11 million.

GUIDANCE:

Integra LifeSciences sees FY2024 EPS of $2.41-$2.57, versus the consensus of $3.04. Integra LifeSciences sees FY2024 revenue of $1.609-1.629 million, versus the consensus of $1.676 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.